{
  "id": 14466261,
  "title": "TD Cowen reiterates Neurocrine Bio stock rating on growth outlook",
  "url": "https://urgent.news/2026/10/14/td-cowen-reiterates-neurocrine-bio-stock-rating-on-growth-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T14:10:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/td-cowen-reiterates-neurocrine-bio-stock-rating-on-growth-outlook-93CH-4949585"
  },
  "original_language": "en",
  "account": "TD Cowen has reaffirmed its Buy rating and $220.00 price target on Neurocrine Biosciences Inc. (NASDAQ:NBIX), highlighting two growth drivers: Crenessity and Vykat. Key opinion leaders and data from TD Cowen’s Therapeutics Conference support the company’s long-term growth potential. Neurocrine Biosciences is considered undervalued, with InvestingPro analysis showing the stock trading below its Fair Value. The firm’s valuation is further bolstered by a low P/E ratio of 19.88 and a PEG ratio of 0.19. Revenue for the last twelve months reached $3.37 billion, with Ingrezza and Crenessity exceeding expectations. Despite safety concerns surrounding Vykat, a number of brokerage firms have maintained positive outlooks on the stock, including RBC Capital, UBS, and H.C. Wainwright.",
  "summary": null,
  "key_points": [
    "TD Cowen reaffirms Buy rating and $220 price target on Neurocrine Bio (NBIX)",
    "Growth drivers: Crenessity and Vykat highlighted by TD Cowen",
    "Neurocrine Bio undervalued with low P/E (19.88) and PEG (0.19) ratios"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}